Last reviewed · How we verify
Goal-directed hemodynamic therapy
At a glance
| Generic name | Goal-directed hemodynamic therapy |
|---|---|
| Sponsor | Klinikum Ludwigshafen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Three Different GHDT ( Goal Hemodynamic Directed Therapy) Strategies for Intraoperative Fluid Management Optimization During Major Abdominal Surgery: A Randomized Controlled Trial (NA)
- Gelaspan vs Crystalloid Therapy in Sepsis (PHASE4)
- Effect of Two Different Fluid Treatment Regimens on Ultrasonographic Upper Airway Measurements (NA)
- Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery (NA)
- CTICU Device Study CRUISE
- GDFT and Postoperative Cognitive Function in Geriatric Cancer Surgery
- Restrictive Fluid Management In Liver Transplantation (REFIL) (NA)
- Hypotension Prediction Index (HPI) and Assisted Fluid Management (AFM) for Perioperative Hemodynamic Optimization in Patients Under General Anesthesia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Goal-directed hemodynamic therapy CI brief — competitive landscape report
- Goal-directed hemodynamic therapy updates RSS · CI watch RSS
- Klinikum Ludwigshafen portfolio CI